This content is machine translated Myelofibrosis Treatment in transition With the introduction of the Janus kinase (JAK) inhibitor ruxolitinib, therapy for myelofibrosis has changed dramatically in recent years. Nevertheless, further innovation is needed, especially in the second line. Promising…
View Post 5 min This content is machine translated Myeloproliferative neoplasms News from a field that is developing rapidly Classic myeloproliferative neoplasms (MPNs) include polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Several sessions at the EHA Congress in mid-June addressed the revision in the guidelines, news on JAK inhibition,…
View Post 4 min This content is machine translated Hematology New possibilities thanks to targeted therapy At the DGHO congress in Vienna, the focus was on new targeted therapies designed to improve the quality of life of patients with malignant hematologic diseases. In particular, medical advances…
